• Exposure to cisplatin with ATR inhibitor

  2025-01-23

  

  Exposure to cisplatin with ATR inhibitor resulted in an increase in cisplatin-DNA adducts, especially in cells with ATM deficiency. This finding indicates that suppressing ATR-Chk1 signaling with VE-822 enhances cisplatin activity by enabling the drug to form DNA adducts. Therefore, VE-822 may incre

• Introduction Lipoxygenases LOXs are key enzymes that catalyz

  2025-01-23

  

  Introduction Lipoxygenases (LOXs) are key enzymes that catalyze the polyunsaturated fatty acids (PUFAs) such as arachidic Tirapazamine (AA), linoleic acid (LA) and others unsaturated fatty acids (Brash, 1999). LOXs are expressed in immune, neural, epithelial, tumor cells and other cells (Claesson,

• Another contributor for the G M arrest

  2025-01-23

  

  Another contributor for the G2/M arrest in A549 and H1299 cells might be p21WAF1/CIP1 which was up-regulated upon ovatodiolide treatment. p21WAF1/CIP1 is a common CDKs inhibitor which blocks inhibitor of catalase G2/M phase progression in various types of cancer cells (Kim et al., 2015, Liberio et a

• The leaves of Bambusa nutans B vulgaris B textilis McClure

  2025-01-23

  

  The leaves of Bambusa nutans, B. vulgaris, B. textilis McClure, B. vulgaris var. vittata, and Dendrocalamus oldhami are reported as promising natural alternatives to synthetic antioxidants as functional food ingredients (Tripathi et al., 2015). Luo et al. (2015), identified two novel flavonoids name

• capreomycin australia It is worth noting that in S cerevisia

  2025-01-23

  

  It is worth noting that in S. cerevisiae, the control of two cell-cycle checkpoints requiring Mcm1 involves two very different mechanisms. At the G1/S transition, Mcm1 transactivation activity is inhibited by Yox1 and Yhp1 repressors, whose expression is periodically regulated through the cell cycle

• br Introduction Increasing number of mycosis infections has

  2025-01-23

  

  Introduction Increasing number of mycosis infections has been reported during the past several years because of the rise in the number of immuno-compromised individuals in subtropical and tropical countries with high mortality and morbidity [1], [2]. Trichophyton mentagrophytes, Trichophyton rubr

• br Materials and methods br Conflict of interest br

  2025-01-23

  

  Materials and methods Conflict of interest Acknowledgments We thank Christine Heiner (Department of Surgery, University of Pittsburgh) for her critical reading of the manuscript. This work was supported by grants from the US National Institutes of Health (R01GM115366, R01CA160417, and R01CA

• br Perspective AA LA and other PUFAs and

  2025-01-23

  

  Perspective AA, LA and other PUFAs and their lipid metabolites play an important role in human diseases. 12/15-LOX which is the metabolic enzyme of them plays an important role in the pathogenesis-related diseases such as atherosclerosis, diabetic nephropathy, neurological diseases and other path

• br Current therapies for metabolic diseases Inborn errors

  2025-01-23

  

  Current therapies for metabolic diseases Inborn errors of metabolism caused by deficiency of particular enzymes due to loss of function mutations or deletions have been treated by decreasing the intake of the enzymatic substrate, supplementation with an essential cofactor or vitamin, increasing m

• br Materials and methods br

  2025-01-22

  

  Materials and methods Results The average body weights for each group of mice over the course of the study are shown in Fig. 2A. The average body weights of the mice in the saline control group and PACAP group increased slightly during the study. In contrast, starting at day 17, the body weigh

• Based on our previous work

  2025-01-22

  

  Based on our previous work [13] and the observation that SNX9 is a partner for ACK, we have investigated interactions involving the SH3 domain of SNX9, and identified for the first time synaptojanin-1 as an alternate partner. This SH3 domain can bind a single site in ACK1, but multiple sites in the

• Although ACE genetic variance does not

  2025-01-22

  

  Although ACE genetic variance does not influence the level of bradykinin significantly, the bradykinin level tends to be affected by ACE inhibitor therapy used by patients. ACE inhibitor reduces the ACE activity that may lead to the accumulation of serum bradykinin. The level of bradykinin tends to

• Although ACE genetic variance does not

  2025-01-22

  

  Although ACE genetic variance does not influence the level of bradykinin significantly, the bradykinin level tends to be affected by ACE inhibitor therapy used by patients. ACE inhibitor reduces the ACE activity that may lead to the accumulation of serum bradykinin. The level of bradykinin tends to

• Illustrated in is the protocol we applied

  2025-01-22

  

  Illustrated in is the protocol we applied for the screens of novel furoic acids as ACL inhibitors. We constructed our furan carboxylate library that contained 1446 2-furoic PF-06463922 derivatives and 501 3-furoic acid derivatives by performing substructural searches of the ZINC database. We limi

• MPC 6827 hydrochloride br Conclusions A large body of eviden

  2025-01-22

  

  Conclusions A large body of evidence indicates that oxidative stress is involved in the pathogenesis of NDDs. Hence, reducing oxidative stress or suppressing its downstream pathways may be beneficial for the treatment of these diseases, especially such chronic diseases as AD or glaucoma. Here we

16163 records 28/1078 page Previous Next First page 上5页 2627282930 下5页 Last page